1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nectar Lifesciences Ltd.

Nectar Lifesciences Ltd.

10.78
INR
-0.56
(-4.94%)
0.68EPS
2.26BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
73.03
73.26
74.72
73.29
83.66
124.09
105.52
68.82
74.41
67.94
75.09
- -
- -
0.24
Basic EPS, GAAP
2.77
2.95
2.42
2.47
2.33
2.12
1.42
-3.27
1.12
-1.08
0.22
-5.07
-13.4
-3.29
Free Cash Flow per Basic Share
6.84
2.85
4.05
6.48
1.43
8.97
10.26
-0.44
3.12
4.62
8.71
5.6
-19.62
- -
Dividend per Share
0.1
0.1
0.12
0.12
0.06
0.06
0.06
0.05
- -
- -
- -
- -
- -
- -
Book Value per Share
41.34
40.22
42.54
44.89
47.21
49.28
50.66
47.36
48.51
47.47
47.68
42.63
29.97
- -
Tangible Book Value per Share
41.34
36.67
39.51
42.33
45.16
47.53
48.91
45.65
46.59
45.27
45.34
40.11
29.92
- -
Basic Weighted Avg Shares
224
224
224
224
224
224
224
224
224
224
224
224
219
211
Sales/Revenue/Turnover
16,378
16,429
16,757
16,437
18,763
27,829
23,664
15,433
16,688
15,237
16,841
- -
- -
50
Operating Margin (%)
12.49
11.59
10.84
9.88
9.18
7.23
6.73
4.02
6.09
-0.34
5.49
- -
- -
-1,740.53
Depreciation Expense
842
766
574
623
643
633
608
603
570
591
607
624
228
5
Net Income, GAAP
621
663
542
553
523
476
318
-733
250
-242
50
-1,137
-2,929
-694
Effective Tax Rate (%)
20.64
21.82
15.02
17.92
16.61
19.08
15.16
- -
26.51
- -
72.66
34.98
- -
- -
Profit Margin (%)
3.79
4.03
3.24
3.37
2.79
1.71
1.34
-4.75
1.5
-1.59
0.3
- -
- -
-1,384.56
Working Capital
1,113
2,128
2,245
2,172
3,513
3,691
3,673
514
3,510
3,403
3,110
2,160
2,229
- -
LT Debt
2,233
2,655
2,454
1,638
2,201
1,656
1,215
1,282
2,911
2,265
1,403
601
- -
- -
Total Equity
9,271
9,020
9,541
10,067
10,587
11,052
11,361
10,620
10,879
10,646
10,693
9,561
5,823
- -
Return on Invested Capital (%)
9.15
8.38
8.22
7.66
7.34
8.05
6.88
- -
4.17
- -
1.44
-2.49
- -
- -
Return on Capital (%)
7.48
7.48
6.85
6.97
6.46
5.9
5.59
- -
3.91
- -
1.67
-7.01
- -
- -
Return on Common Equity (%)
6.92
7.25
5.84
5.64
5.06
4.4
2.84
-6.67
2.33
-2.25
0.47
-11.23
-38.08
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
224
194
194
Market Capitalization
4,373
1,809
2,263

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,530
- -
Cash, Cash Equivalents & STI
- -
1,251
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
3
- -
Total Current Liabilities
- -
301
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.76%
-9.79%
-39.1%
Free Cash Flow
-73%
-230.15%
-441.35%
Net Income, GAAP
-304.58%
-533.93%
157.64%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3,588
57
- -
- -
- -
2026
- -
50
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.13
-0.01
0.35
-5.8
-5.07
2026
-2.82
-0.01
0.64
-3.38
-13.4
2027
-0.79
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sanjiv Goyal
Full Time Employees
111
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Godrej Eternia Chandigarh UT India 160002
IPO Date
Jun 22, 2005
Website
neclife.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nectar Lifesciences Limited, incorporated in 1995 and headquartered in Chandigarh, India, manufactures, markets and distributes pharmaceutical products with a focus on active pharmaceutical ingredients, intermediates and finished dosage forms, particularly in the cephalosporin antibiotics segment; core offerings include APIs such as Cefixime, Cefuroxime Axetil (amorphous and crystalline), Cefotaxime Sodium and Ceftriaxone Sodium, alongside contract manufacturing of cephalosporin solid dosage forms like tablets, capsules, dry powder oral suspensions, granules and injectables; additional products encompass menthol and mint derivatives, empty hard gelatin capsules, rapid test kits for conditions including HIV, dengue, syphilis, pregnancy and troponin I, as well as anti-inflammatory drugs and cardiovascular medications. The company operates manufacturing facilities compliant with EUGMP guidelines and holding approvals from regulators including PMDA Japan, ANVISA Brazil and COFEPRIS Mexico, spanning over 242,000 square meters near Chandigarh in Punjab and Himachal Pradesh; it serves markets in over 45 countries with a strong export focus on anti-infectives and lifesciences products. In July 2025, Nectar Lifesciences signed a definitive Business Transfer Agreement to divest its core API and formulations business to Ceph Lifesciences Private Limited for INR 1,270 crore on a slump sale basis, alongside an Asset Purchase Agreement for its menthol business assets valued at INR 20 crore; these transactions, approved by the board and pending shareholder and regulatory nods with expected completion by September 20, 2025, form part of a strategic restructuring to streamline operations, reduce debt, pursue new growth segments and enhance shareholder value.